Skip to main content
MedPathMedPath Home
Clinical Trials/NCT02156999
NCT02156999
Recruiting
Phase 4

Changes of Bone Turnover Markers and Bone Mineral Density After Treatment in Osteoporotic Patients

Shinshu University1 site in 1 country100 target enrollmentJune 2014
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsOsteoporosis

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Osteoporosis
Sponsor
Shinshu University
Enrollment
100
Locations
1
Primary Endpoint
Changes of bone mineral density
Status
Recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

To examine the changes of bone mineral density and bone turnover markers after Bonviva treatment in osteoporotic patients

Registry
clinicaltrials.gov
Start Date
June 2014
End Date
December 2025
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Yukio Nakamura

Assistant professor

Shinshu University

Eligibility Criteria

Inclusion Criteria

  • •Osteoporosis

Exclusion Criteria

  • •Kidney, parathyroid, congenital bone metabolic disease

Outcomes

Primary Outcomes

Changes of bone mineral density

Time Frame: every 4-6 months

To examine the changes of bone mineral density for the purpose of the effectiveness of the drug

Secondary Outcomes

  • Improvement of bone turnover markers(Every 3-6 months)

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Effect on bone turnover and Bone Mineral Density (BMD) of low dose oral silicon as an adjunct to calcium/vitamin D3 in a randomised, placebo-controlled trial
ISRCTN57103074Bio Minerals N.V. (Belgium)184
Active, not recruiting
Phase 1
A Study to investigate Bone turnover Markers in patients planned to receive tofacitinibRheumatoid arthritisMedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2018-003162-13-ITAZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA30
Completed
Not Applicable
To Investigate the Impact of a Nutritional Supplement on Bone Turnover Markers in Indian Healthy Premenopausal Women (25- 45 Years) After 6 Months of InterventionGrowth and Development
NCT03155269GlaxoSmithKline114
Active, not recruiting
Phase 1
Bone turnover markers as predictors of treatment break outcomeOsteoporosisMedDRA version: 19.0 Level: LLT Classification code 10031289 Term: Osteoporosis, unspecified System Organ Class: 100000004859Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2016-003110-27-DKBente Lomholt Langdahl, Dept. of Endocrinology and Internal Medicine, Aarhus University Hospital140
Recruiting
Not Applicable
Clinical investigation of change of bone-related marker between denosumab and zoledronic acid in patients with treatment-naive,bone-metastasis prostate cancer:prospective, multiinstitutional,cohort studytreatment-naive prostate cancer with bone metastasis
JPRN-UMIN000018268Department of Renal and Urologic Surgery, Asahikawa Medical University50